Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Antimicrob Agents Chemother ; 45(8): 2304-8, 2001 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-11451689

RESUMO

The efficacies of orally (p.o.) dosed linezolid and intravenously (i.v.) dosed vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in rabbits with experimental aortic-valve endocarditis were investigated. After endocarditis was established with a recent clinical MRSA isolate, rabbits were dosed for 5 days with linezolid (p.o., three times a day) at either 25, 50, or 75 mg/kg of body weight or vancomycin (i.v., twice a day) at 25 mg/kg. The 25-mg/kg linezolid group had a high mortality rate and bacterial counts in the valve vegetations that were not different from those of the controls. Linezolid dosed p.o. at 50 and 75 mg/kg and i.v. vancomycin produced statistically significant reductions in bacterial counts compared to those of the untreated controls. The reduced bacterial counts and culture-negative valve rates for the animals treated with linezolid at 75 mg/kg were similar to those for the vancomycin-treated animals. Concentrations of linezolid in plasma were determined at several points in the dosing regimen. These results suggest that the efficacy of linezolid in this infection model is related to trough levels in plasma that remain above the MIC for this microorganism. At the ineffective dose of linezolid (25 mg/kg) the concentration at sacrifice was 0.045 times the MIC, whereas the concentrations of linezolid in plasma in the 50- and 75-mg/kg groups were 2 and 5 times the MIC at sacrifice, respectively. The results from this experimental model suggest that the oxazolidinone linezolid may be effective for the treatment of serious staphylococcal infections when resistance to other antimicrobials is present.


Assuntos
Acetamidas/uso terapêutico , Antibacterianos/uso terapêutico , Endocardite Bacteriana/tratamento farmacológico , Doenças das Valvas Cardíacas/tratamento farmacológico , Resistência a Meticilina , Oxazolidinonas/uso terapêutico , Infecções Estafilocócicas/tratamento farmacológico , Administração Oral , Animais , Valva Aórtica/efeitos dos fármacos , Contagem de Colônia Microbiana , Endocardite Bacteriana/microbiologia , Doenças das Valvas Cardíacas/microbiologia , Rim/efeitos dos fármacos , Linezolida , Meticilina/farmacologia , Testes de Sensibilidade Microbiana , Coelhos , Infecções Estafilocócicas/microbiologia , Staphylococcus aureus/efeitos dos fármacos , Staphylococcus aureus/isolamento & purificação , Vancomicina/administração & dosagem , Vancomicina/farmacologia
2.
J Antimicrob Chemother ; 47(3): 349-52, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11222569

RESUMO

A rabbit endocarditis model was used to test the efficacy of oral linezolid and iv vancomycin. Twenty-four hours after catheter placement across the aortic valve, rabbits were infected with 3.5 x 10(6) cfu of Staphylococcus aureus (UC-9258). Two days after infection, control rabbits were killed, and treated rabbits were given 5 days of therapy with linezolid at 8 h intervals (tds) using either 25, 50 or 75 mg/kg/dose, or vancomycin at 12 h intervals (bd) using 25 mg/kg/dose. Linezolid at 75 and 50 mg/kg, and vancomycin significantly reduced S. aureus in aortic valve vegetations compared with the control. Linezolid at 25 mg/kg was ineffective. The efficacy of 75 and 50 mg/kg linezolid was related to maintenance of plasma drug levels near or above the linezolid MIC for UC-9258 (2 mg/L).


Assuntos
Acetamidas/uso terapêutico , Antibacterianos/uso terapêutico , Endocardite Bacteriana/tratamento farmacológico , Oxazolidinonas/uso terapêutico , Infecções Estafilocócicas/tratamento farmacológico , Administração Oral , Animais , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Endocardite Bacteriana/microbiologia , Injeções Intravenosas , Linezolida , Masculino , Coelhos , Organismos Livres de Patógenos Específicos , Infecções Estafilocócicas/microbiologia , Staphylococcus aureus/efeitos dos fármacos , Resultado do Tratamento , Vancomicina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...